Skip to search formSkip to main contentSkip to account menu

gabapentin enacarbil

Known as: Gabapentine enacarbil, Gabapentinum enacarbilum, Gabapentina enacarbilo 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event… 
2018
2018
Objective Gabapentin and its prodrug are candidate therapeutic agents for akathisia. An open-label pilot study was conducted to… 
2015
2015
OBJECTIVE: To determine the effect of GEn on QoL in adults with moderate-to-severe and severe primary RLS. BACKGROUND: Poor QoL… 
Review
2014
Review
2014
Gabapentin does not decrease the frequency of migraine headaches and is not recommended for prophylactic therapy. 
2011
2011
Background. The efficacy of gabapentin in some patients with postherpetic neuralgia (PHN) may be limited by suboptimal drug… 
2011
2011
UNLABELLED Gabapentin enacarbil (GEn) is a prodrug of gabapentin that is effective in restless legs syndrome (RLS) and has dose… 
Review
2011
Review
2011
Introduction: Gabapentin enacarbil is a new treatment for restless legs syndrome (RLS). It is a prodrug of the anticonvulsant… 
2011
2011
Gabapentin enacarbil (Horizant-GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved… 
2009
2009
Le medicament Gabapentine enacarbil est synthetise et purifie a partir d'intermediaires comme un carbamate ou carbonate de 1…